CTLA4 and glioblastoma: Currently the clinical trial NCT04003649 is investigating whether IL13Ra2 CAR T cells work better alone or in combination with nivolumab (anti-PD-1) and ipilimumab (anti-CTLA4) to treat recurrent and refractory GBM.